2. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterialhypertension: The Task Force for the management of arterial hypertension of the European Societyof Cardiology and the European Society of Hypertension. J Hypertens 2018; 36(10):1953–2041. doi:10.1097/HJH.0000000000001940.

3. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascularmortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet.2002; 360:1903–13.

4. Chester E.M., Agamanolis D.P., Banker B.Q., Victor M. Hypertensive encephalopathy: aclinicopathologic study of 20 cases. Neurology 1978; 28: 928–39.

5. Cremer A., Amraoui F., Lip G.Y. et al. From malignant hypertension to hypertension-MOD: amodern definition for an old but still dangerous emergency. J Hum Hypertens. 2016; 30: 463–66.doi: 10.1038/jhh.2015.112.

6. Grassi D., O’Flaherty M., Pellizzari M. et al. Hypertensive urgencies in the emergency department:evaluating blood pressure response to rest and to antihypertensive drugs with different profiles. J ClinHypertens (Greenwich). 2008; 10: 662–67. doi: 10.1111/j.1751-7176.2008.00001.x.

7. Dickinson H.O., Mason J.M., Nicolson D.J. et al. Lifestyle interventions to reduce raised bloodpressure: a systematic review of randomized controlled trials. J Hypertens. 2006; 24: 215–33.

8. Lim S.S., Vos T., Flaxman A.D. et al. A comparative risk assessment of burden of disease and injuryattributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysisfor the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224–60. doi: 10.1016/S0140-6736(12)61766-8.

9. http://grls.rosminzdrav.ru (date of access – 10.05.2020) (In Russ.)].

10.Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidencein hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overviewand meta-analyses. J Hypertens. 2015; 33: 1321–41. doi: 10.1097/HJH.0000000000000614.

11.Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressurelowering treatment inhypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensivedrugs: meta-analyses of randomized trials. J Hypertens. 2016; 34: 1921–32. doi: 10.1097/HJH.0000000000001052.

12.Kronish I.M., Woodward M., Sergie Z. et al. Meta-analysis: impact of drug class on adherence toantihypertensives. Circulation. 2011; 123: 1611–21. doi: 10.1161/CIRCULATIONAHA.110.983874.

13.Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcomeincidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and metaanalyses of randomized trials. J Hypertens. 2017; 35: 2150–60. doi: 10.1097/HJH.0000000000001547.

14.Ettehad D., Emdin C.A., Kiran A. et al. Blood pressure lowering for prevention of cardiovasculardisease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–67. doi: 10.1016/S0140-6736(15)01225-8.

15.Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidencein hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses.J Hypertens. 2015; 33: 195–211. doi: 10.1097/HJH.0000000000000447.

16.Corrao G., Zambon A., Parodi A. et al. Discontinuation of and changes in drug therapy forhypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008; 26:819–24. doi: 10.1097/HJH.0b013e3282f4edd7.

17.Brown M.J., Williams B., Morant S.V. et al. Effect of amiloride, or amiloride plushydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure(PATHWAY-3): a parallelgroup, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol.2016; 4: 136–47. doi: 10.1016/S2213-8587(15)00377-0.

18.Rimoldi S.F., Messerli F.H., Chavez P. et al. Efficacy and safety of calcium channel blocker/diureticscombination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich). 2015;17(3): 193–99. doi: 10.1111/jch.12462.

19.Lip G.Y., Felmeden D.C., Dwivedi G. Antiplatelet agents and anticoagulants for hypertension.Cochrane Database Syst Rev. 2011; 12: CD003186. doi: 10.1002/14651858.CD003186.

20.Collaborative overview of randomized of antiplatelet therapy – I: prevention of death, myocardialinfarction, and stroke by prolonged anti-platelet in various categories of patients. AntiplateletTrialists' Collaboration. BMJ. 1994; 308: 81–106.

21.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ.2002; 324: 71–86.

22. Juul-Moller S., Edvardsson N., Jahnmatz B. et al. Double-blind trial of aspirin in primary preventionof myocardial infarction in patients with chronic angina pectoris. Lancet. 1992; 340: 1412–25.

23. Gupta P., Patel P., Strauch B. et al. Biochemical screening for nonadherence is associated with bloodpressure reduction and improvement in adherence. Hypertension. 2017; 70: 1042–48. doi: 10.1161/HYPERTENSIONAHA.117.09631.

24.Makani H., Bangalore S., Desouza K.A. et al. Efficacy and safety of dual blockade of the reninangiotensin system: meta-analysis of randomised trials. BMJ. 2013; 346: f360. doi: 10.1136/bmj.f360.

25. Чазова И.Е., Мычка В.Б. Новые возможности в лечении больных с метаболическим синдромом (результаты исследования ALMAZ). Системные гипертензии. 2006; 2: 14–17.